Rare missense variants in the SH3 domain of PSTPIP1 are associated with hidradenitis suppurativa.

Autor:	Morales-Heil DJ; Department of Medicine, Division of Rheumatology, Washington University, St. Louis, MO, USA., Cao L; Department of Medicine, Division of Rheumatology, Washington University, St. Louis, MO, USA., Sweeney C; Department of Dermatology, St. Vincent's University Hospital, Dublin, Ireland., Malara A; Department of Dermatology, St. Vincent's University Hospital, Dublin, Ireland., Brown F; Department of Anesthesiology, Washington University, St. Louis, MO, USA., Milam P; Department of Internal Medicine, Division of Dermatology, Ohio State University, Columbus, OH, USA., Anadkat M; Department of Medicine, Division of Dermatology, Washington University, St. Louis, MO, USA., Kaffenberger J; Department of Internal Medicine, Division of Dermatology, Ohio State University, Columbus, OH, USA., Kaffenberger B; Department of Internal Medicine, Division of Dermatology, Ohio State University, Columbus, OH, USA., Nagele P; Department of Anesthesiology, Washington University, St. Louis, MO, USA., Kirby B; Department of Dermatology, St. Vincent's University Hospital, Dublin, Ireland., Roberson EDO; Department of Medicine, Division of Rheumatology, Washington University, St. Louis, MO, USA.; Department of Genetics, Washington University, St. Louis, MO, USA.
Jazyk:	angličtina
Zdroj:	HGG advances [HGG Adv] 2023 Mar 13; Vol. 4 (2), pp. 100187. Date of Electronic Publication: 2023 Mar 13 (Print Publication: 2023).
DOI:	10.1016/j.xhgg.2023.100187
Abstrakt:	Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease for which few treatment options are available. While most HS is sporadic, some rare kindred show a high-penetrance, autosomal-dominant inheritance. We wanted to identify rare variants that could contribute to HS risk in sporadic cases using candidate gene sequencing. We ultimately identified 21 genes for our capture panel. We included genes of the γ-secretase complex (n = 6) because rare variants in these genes sometimes cause familial HS. We added Notch receptor and ligand genes (n = 13) because γ-secretase is critical for processing Notch receptor signaling. Clinically, some people with PAPA (pyogenic arthritis, pyoderma gangrenosum, and acne) syndrome, a rare inflammatory disease, have concurrent HS. Rare variants in PSTPIP1 are known to cause PAPA syndrome, so we included PSTPIP1 and PSTPIP2 in the capture panel. We screened 117 individuals with HS for rare variations and calculated the expected burden using Genome Aggregation Database (gnomAD) allele frequencies. We discovered two pathogenic loss-of-function variants in NCSTN . This class of NCSTN variant can cause familial HS. There was no increased burden of rare variations in any γ-secretase complex gene. We did find that individuals with HS had a significantly increased number of rare missense variants in the SH3 domain of PSTPIP1 . This finding, therefore, implicates PSTPIP1 variation in sporadic HS and further supports dysregulated immunity in HS. Our data also suggests that population-scale HS genetic research will yield valuable insights into disease pathology. Competing Interests: B. Kaffenberger has consulted for and received clinical trial funds from Novartis. B. Kirby has received clinical trial support from AbbVie, Almirall, Janssen, Merck Sharpe Dolme, Moonlake, Novartis, Pfizer, and UCB BioPharma; been a consultant for AbbVie, Almirall, Celgene, Janssen, Merck Sharpe Dolme, Moonlake, Novartis, Pfizer, and UCB; received honoraria from AbbVie, Alimrall, Celgene, Janssen, Lilly, Moonlake, Novartis, Pfizer, and UCB; and been on scientific advisory boards for AbbVie, Almirall, Celgene, Janssen, Lilly, Moonlake, Novartis, Pfizer, and UCB. D.J.M.-H. was a postdoctoral fellow during the research and writing of this paper but has since become an employee of Pfizer and holds stock in the company. J.K. has received clinical trial support from XBiotech and UCB BioPharma. M.A. has served as a consultant and/or advisor for ImClone, Bristol Myers Squibb, Astra Zeneca, Therakos, Aspire Bariatrics, Biogen, Amgen, Veloce, Adgero, Eli Lilly, Abbvie, UCB Biopharma, Innovaderm, Boehringer-Ingelheim, OnQuality, Novocure, Springworks, BioLinq, and Protagonist and has served as a principal investigator for InflamRx, Biogen, Astra Zeneca, Novartis, Boehringer-Ingelheim, Lutris, OnQuality, UCB BioPharma, InflamRx, Eli Lilly, InCyte, Abbvie, Moonlake, AnaptysBio, Hana Biosciences, Xoma, Moonlake, Moberg, Veloce, Biogen, Xbiotech, and Chemocentryx. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu